Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
Authors
Keywords
Tuberculosis, Drug research and development, Phase III clinical investigation, Phase II clinical investigation, Drug therapy, Mycobacterium tuberculosis, Clinical trials, Toxicity
Journal
PLOS MEDICINE
Volume 16, Issue 7, Pages e1002851
Publisher
Public Library of Science (PLoS)
Online
2019-07-10
DOI
10.1371/journal.pmed.1002851
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Advances in clinical trial design for development of new TB treatments: A call for innovation
- (2019) Christian Lienhardt et al. PLOS MEDICINE
- Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis: A Randomized Controlled Trial
- (2018) Gustavo E Velásquez et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
- (2018) Marjorie Z. Imperial et al. NATURE MEDICINE
- Target regimen profiles for treatment of tuberculosis: a WHO document
- (2017) Christian Lienhardt et al. EUROPEAN RESPIRATORY JOURNAL
- High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
- (2017) Martin J Boeree et al. LANCET INFECTIOUS DISEASES
- Challenges in the clinical assessment of novel tuberculosis drugs
- (2016) Kelly E. Dooley et al. ADVANCED DRUG DELIVERY REVIEWS
- A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)
- (2016) Patrick P. J. Phillips et al. BMC Medicine
- Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy
- (2016) Isobella Honeyborne et al. BMC Medicine
- Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure
- (2016) A. Jayakumar et al. JOURNAL OF CLINICAL MICROBIOLOGY
- A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
- (2015) Martin J. Boeree et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline
- (2015) Andreas H. Diacon et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis
- (2015) Derek J. Sloan et al. CLINICAL INFECTIOUS DISEASES
- Adaptive clinical trials in tuberculosis: applications, challenges and solutions
- (2015) G. R. Davies et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis
- (2015) R. Dawson et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Transcriptional Adaptation of Drug-tolerantMycobacterium tuberculosisDuring Treatment of Human Tuberculosis
- (2015) Nicholas D. Walter et al. JOURNAL OF INFECTIOUS DISEASES
- Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
- (2015) Rodney Dawson et al. LANCET
- Month 2 Culture Status and Treatment Duration as Predictors of Recurrence in Pulmonary Tuberculosis: Model Validation and Update
- (2015) Robert S. Wallis et al. PLoS One
- The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations
- (2014) Ruth Bowness et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The Molecular Bacterial Load Assay Replaces Solid Culture for Measuring Early Bactericidal Response to Antituberculosis Treatment
- (2014) I. Honeyborne et al. JOURNAL OF CLINICAL MICROBIOLOGY
- PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis
- (2014) M. T. Coleman et al. Science Translational Medicine
- Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary Tuberculosis
- (2013) Andreas H. Diacon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and Relapse
- (2013) Patrick P. J. Phillips et al. PLoS One
- Month 2 Culture Status and Treatment Duration as Predictors of Tuberculosis Relapse Risk in a Meta-Regression Model
- (2013) Robert S. Wallis et al. PLoS One
- Time to positivity in liquid culture predicts colony forming unit counts of Mycobacterium tuberculosis in sputum specimens
- (2013) Andreas H. Diacon et al. TUBERCULOSIS
- Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment
- (2013) Sven O Friedrich et al. Lancet Respiratory Medicine
- A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture
- (2012) E. Chigutsa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis
- (2012) Patrick P. J. Phillips et al. JOURNAL OF INFECTIOUS DISEASES
- 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
- (2012) Andreas H Diacon et al. LANCET
- Molecular Bacterial Load Assay, a Culture-Free Biomarker for Rapid and Accurate Quantification of Sputum Mycobacterium tuberculosis Bacillary Load during Treatment
- (2011) Isobella Honeyborne et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis
- (2009) Susan E. Dorman et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis
- (2008) R. Rustomjee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More